What’s Next for NGS? A Conversation with Eli Glezer and Shawn Levy

0

[ Click the lower right icon to view fullscreen with transcript ^ ]

It’s been a busy and exciting time for next-generation sequencing (NGS). Several new companies have recently entered the U.S. market, which has been dominated by just one company—Illumina—for the past decade.

Leaders from two of these new companies are Eli Glezer, PhD, CSO and cofounder of Singular Genomics, and Shawn Levy, PhD, senior vice president at Element Biosciences.

In this conversation with GEN’s Julianna LeMieux, PhD, Glezer and Levy dug into the impact that emerging NGS platforms and technologies will have in this space, what their companies’ priorities are, and how they plan to carve a niche for themselves. They discuss the accuracy, speed, cost, output, and flexibility of their platforms, the various applications, limitations, and nuances of the technologies, and other areas of omics that the platforms are poised to enter.

Previous articleLessons from the COVID Crisis: An Interview with Peter Hotez
Next articleThe Future of Synthetic Biology: A Discussion with Eben Bayer, Deepak Dugar, and Emily Leproust